Olanzapine‐Associated Diabetes Mellitus

Pharmacotherapy - Tập 22 Số 7 - Trang 841-852 - 2002
Elizabeth A. Koller1, P. Murali Doraiswamy2
1Division of Metabolic and Endocrine Drug Products, Center for Drug Evaluation and Review, Food and Drug Administration, Rockville, Maryland
2the Departments of Psychiatry and Medicine, Duke University Medical Center, Durham, North Carolina.

Tóm tắt

Study Objective. To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine.Design. Retrospective, epidemiologic survey of spontaneously reported adverse events related to olanzapine therapy.Setting. Government‐affiliated drug evaluation center.Patients. Two hundred thirty‐seven patients with olanzapine‐associated diabetes or hyperglycemia.Intervention. One hundred ninety‐six cases from January 1994‐May 15, 2001, were identified with the United States Food and Drug Administration's MedWatch Drug Surveillance System, and 41 cases published through May 15, 2001, were identified with MEDLINE or through meeting abstracts.Measurements and Main Results. Of the 237 cases, 188 were new‐onset diabetes, 44 were exacerbations of preexistent disease, and 5 could not be classified. Mean patient age for newly diagnosed cases was 40.7 ± 12.9 years and male:female ratio was 1.8. Seventy‐three percent of all cases of hyperglycemia appeared within 6 months of start of olanzapine therapy. Eighty patients had metabolic acidosis or ketosis, 41 had glucose levels of 1000 mg/dl or greater, and 15 patients died. When olanzapine was discontinued or the dosage decreased, 78% of patients had improved glycemic control. Hyperglycemia recurred in 8 of 10 cases with rechallenge.Conclusions. Number of reports, temporal relationship to start of olanzapine therapy, relatively young age, and improvement on drug withdrawal suggest that olanzapine may precipitate or unmask diabetes in susceptible patients.

Từ khóa


Tài liệu tham khảo

Eli Lilly and Company.Zyprexa home page. Available fromhttp:www.zyprexa.com. Accessed June 8 2001.

10.1345/aph.17215

10.1007/s11940-001-0039-0

10.1517/14656566.2.4.667

10.1016/S0033-3182(98)71301-5

10.1517/14656566.1.5.935

10.1345/aph.19327

10.1345/aph.10280

Braak Ter GI, 1998, Het hyperglykemisch dehydratiesyndroom [comment], Ned Tijdschr Geneeskd, 142, 2262

10.1345/aph.19390

10.4088/JCP.v59n1208c

Goldstein LE, 1999, New‐onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment, Psychosomatics, 44, 778

10.2337/diacare.22.6.1002

IqbalN OldanRL BairdG et al.Atypical antipsychotic‐induced diabetes mellitus. Poster presentation at the annual meeting of the American Psychiatric Association Chicago May 1318 2000.

10.1176/appi.ajp.159.1.150-a

Koller E, 2001, Atypical antipsychotic drugs and hyperglycemia in adolescents [letter], JAMA, 286, 2547, 10.1001/jama.286.20.2542

Lindenmayer JP, 1999, Olanzapine‐induced ketoacidosis with diabetes mellitus [letter], Am J Psychiatry, 156, 9, 10.1176/ajp.156.9.1471

Meunch J, 2001, Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature, J Am Board Fam Pract, 14, 278

10.1176/ajp.156.6.970

10.1046/j.1464-5491.2000.00296.x

10.1345/aph.10178

10.1592/phco.21.17.1448.34421

10.1067/mpd.2001.114016

SmithL.Hyperglycemia in patients treated with olanzapine. Poster presentation at the American Psychiatric Association Institute on Psychiatric Services meeting New Orleans October 29November 2 1999.

10.4088/JCP.v62n1214b

10.1007/s001150050520

WilsonER D'SouzaL SarkarN NewtonM.New‐onset diabetes and ketoacidosis with atypical antipsychotics. Presented at the annual meeting of the American College of Neuropsychopharmacology Acapulco Mexico December 12 1999.

10.1016/S0006-3223(98)00100-0

10.1016/S0210-5705(01)70138-0

10.1067/mlc.2001.111515

10.1111/j.1600-0404.1984.tb00804.x

10.1016/S0002-9343(01)00806-3

10.2165/00002018-200124130-00004

Turnbull DM, 1985, The effect of valproate on blood metabolite concentrations in spontaneously diabetic, ketoacidotic, BB/E Wistar rats, Diabetes Res, 2, 45

10.1097/00005792-197203000-00001

10.2337/diab.20.4.228

Kenny SJ, 1995, Diabetes in America, 2nd ed. Publication no. 95–1468, 47

IMS Health.IMS Health‐National Disease and Therapeutic Index. Plymouth Meeting PA.

10.1016/S0002-9343(01)01000-2

Andreasen NC, 1994, Diagnostic and statistical manual of mental disorders, 273

10.4088/JCP.v61n0514

Usall I, 2001, Gender differences in mood disorders: a literature review, Actas Esp Psiquiatr, 29, 269

Kaplan HI, 1997, Kaplan and Sadock's synopsis of psychiatry, 1049

Ammon HR, 1973, Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat, J Pharmacol Exp Ther, 187, 423

10.1007/BF00421177

10.1001/jama.1995.03530010043033

Bennett BS, 1977, Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse events, Am J Hosp Pharm, 34, 931

10.1046/j.1365-2125.1999.00060.x

10.1136/bmj.2.5599.193

10.1016/S0895-4356(97)00241-2

10.1046/j.1365-2125.1997.00616.x

Rogers Smith A, 1988, Physician knowledge, attitudes, and behavior related to reporting adverse drug events, Arch Intern Med, 48, 1596, 10.1001/archinte.1988.00380070090021

Tyler LS, 1992, Hospital pharmacy compliance with JCAHO standards and ASHP guidelines for reporting adverse drug reactions, Am J Hosp Pharm, 49, 845

IMS Health.IMS Health‐National Prescription Audit Plus. Plymouth Meeting PA.

KwongK CavazzoniP HornbuckleK et al.Higher incidences of diabetes mellitus during exposure to antipsychotics: findings from a retrospective cohort study in the U.S. Poster presentation at the 41st annual meeting of the New Clinical Drug Evaluation Unit Phoenix May 2831 2001.

10.1016/0165-1781(89)90183-2

Schultz SK, 1999, Impaired glucose tolerance and abnormal movements in patients with schizophrenia, Am J Psychiatry, 156, 640, 10.1176/ajp.156.4.640

10.1176/ajp.151.9.1395a

10.1176/appi.ajp.157.6.975

10.4088/JCP.v60n0809f

10.1176/appi.psy.41.4.369

Kropp S, 2001, Olanzapine‐related hyperglycemia in a nondiabetic woman [letter], Can J Psychiatry, 46, 457, 10.1177/070674370104600528

10.1345/aph.1A157

10.4088/JCP.v61n1111b

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 22 Số 7

841-852

Thông tin tác giả